Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04765384
Registration number
NCT04765384
Ethics application status
Date submitted
19/02/2021
Date registered
21/02/2021
Date last updated
25/05/2025
Titles & IDs
Public title
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
Query!
Scientific title
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
Query!
Secondary ID [1]
0
0
VAC31518COV2004
Query!
Secondary ID [2]
0
0
CR108962
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
HORIZON 1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COVID-19 Prevention
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Other - Ad26.COV2.S
Experimental: Groups 1-4: Ad26.COV2.S (One Dose) - Participants who are previously vaccinated (Group 1-3) and participants who are vaccine naïve (Group 4) will receive single dose of Ad26.COV2.S vaccine at standard dose level on Day 1. Participants from group 4 who are no longer pregnant may receive single booster dose of Ad26.COV2.S vaccine at standard dose level.
Treatment: Other: Ad26.COV2.S
Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Adult Participants With Solicited Local Adverse Events (AEs) for 7 Days Post First Vaccination
Query!
Assessment method [1]
0
0
Number of adult participants with solicited local AEs for 7 days post first vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited AEs were used to assess the reactogenicity of the study vaccine and were pre-defined as local (at the injection site) AEs for which participants were specifically asked and which were noted by participants in their reactogenicity diary for 7 days post first vaccination (day of first vaccination and the subsequent 7 days). Solicited local AEs are injection site pain/tenderness, erythema, swelling at the vaccination site.
Query!
Timepoint [1]
0
0
From first vaccination on Day 1 up to 7 days post first vaccination (up to Day 8)
Query!
Primary outcome [2]
0
0
Number of Adult Participants With Solicited Systemic AEs for 7 Days Post First Vaccination
Query!
Assessment method [2]
0
0
Number of adult participants with solicited systemic AEs for 7 days post first vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited AEs were used to assess the reactogenicity of the study vaccine and were predefined as systemic AEs for which participants were specifically asked and which were noted by participants in their reactogenicity diary for 7 days post first vaccination. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post first vaccination (day of first vaccination and the subsequent 7 days) for the following solicited systemic AEs: fatigue, headache, nausea, myalgia.
Query!
Timepoint [2]
0
0
From first vaccination on Day 1 up to 7 days post first vaccination (up to Day 8)
Query!
Primary outcome [3]
0
0
Number of Adult Participants With Unsolicited AEs for 28 Days Post First Vaccination
Query!
Assessment method [3]
0
0
Number of adult participants with unsolicited AEs for 28 days post first vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were defined as AEs for which the participants were not specifically questioned in the participant's reactogenicity diary.
Query!
Timepoint [3]
0
0
From first vaccination on Day 1 up to 28 days post first vaccination (up to Day 29)
Query!
Primary outcome [4]
0
0
Number of Adult Participants With Serious Adverse Events (SAEs) From First Vaccination Until End of the Study (EOS)
Query!
Assessment method [4]
0
0
Number of adult participants with SAEs from first vaccination until EOS were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. SAEs were defined as any untoward medical occurrence that at any dose results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.
Query!
Timepoint [4]
0
0
From first vaccination on Day 1 until end of study (up to post-partum [PP] Day 366 [Day 15 up to Day 554])
Query!
Primary outcome [5]
0
0
Number of Adult Participants With Adverse Events of Special Interest (AESIs) From First Vaccination Until EOS
Query!
Assessment method [5]
0
0
Number of adult participants with AESIs from first vaccination until EOS were reported. Thrombosis with thrombocytopenia syndrome (TTS) in adults was considered an AESI in this study. TTS is a syndrome characterized by a combination of both a thrombotic event and thrombocytopenia.
Query!
Timepoint [5]
0
0
From first vaccination on Day 1 until end of study (up to PP Day 366 [Day 15 up to Day 554])
Query!
Primary outcome [6]
0
0
Number of Adult Participants With Medically Attended Adverse Events (MAAEs) Until 6 Months Post First Vaccination
Query!
Assessment method [6]
0
0
Number of adult participants with MAAEs until 6 months post first vaccination was reported. MAAEs were defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically attended visits. New onset of chronic diseases was collected as part of the MAAEs.
Query!
Timepoint [6]
0
0
From first vaccination on Day 1 until 6 months post first vaccination (up to Day 183)
Query!
Primary outcome [7]
0
0
Number of Adult Participants With AEs Leading to Study Discontinuation
Query!
Assessment method [7]
0
0
Number of adult participants with AEs leading to study discontinuation were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. All AEs leading to discontinuation from the study (regardless of the causal relationship) were reported for all adult participants from the moment of first vaccination until completion of the participant's last study-related procedure.
Query!
Timepoint [7]
0
0
From first vaccination on Day 1 until end of study (up to PP Day 366 [Day 15 up to Day 554])
Query!
Primary outcome [8]
0
0
Serological Response to Vaccination as Measured by S-Enzyme-linked Immunosorbent Assay (S-ELISA) in Adult Participants 28 Days Post First Vaccination
Query!
Assessment method [8]
0
0
Serological response to vaccination as measured by S-ELISA in adult participants 28 days post first vaccination was reported.
Query!
Timepoint [8]
0
0
28 days post first vaccination on Day 1 (at Day 29)
Query!
Secondary outcome [1]
0
0
Group 4: Number of Adult Participants With Solicited Local AEs for 7 Days Post Booster Vaccination
Query!
Assessment method [1]
0
0
Number of adult participants with solicited local AEs for 7 days post booster vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited AEs were used to assess the reactogenicity of the study vaccine and were pre-defined as local (at the injection site) AEs for which participants were specifically asked and which were noted by participants in their reactogenicity diary for 7 days post booster vaccination (day of booster vaccination and the subsequent 7 days). Solicited local AEs are: injection site pain/tenderness, erythema, swelling at the vaccination site.
Query!
Timepoint [1]
0
0
7 days post booster vaccination (Day 84 up to Day 371)
Query!
Secondary outcome [2]
0
0
Group 4: Number of Adult Participants With Solicited Systemic AEs for 7 Days Post Booster Vaccination
Query!
Assessment method [2]
0
0
Number of adult participants with solicited systemic AEs for 7 days post booster vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited AEs were used to assess the reactogenicity of the study vaccine and were predefined as systemic AEs for which participants were specifically asked and which were noted by participants in their reactogenicity diary for 7 days post booster vaccination. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (day of booster vaccination and the subsequent 7 days) for the following solicited systemic AEs: fatigue, headache, nausea, myalgia.
Query!
Timepoint [2]
0
0
7 days post booster vaccination (Day 84 up to Day 371)
Query!
Secondary outcome [3]
0
0
Group 4: Number of Adult Participants With Unsolicited AEs for 28 Days Post Booster Vaccination
Query!
Assessment method [3]
0
0
Number of adult participants with unsolicited AEs for 28 days post booster vaccination was reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs were defined as AEs for which the participants were not specifically questioned in the participant's reactogenicity diary.
Query!
Timepoint [3]
0
0
28 days post booster vaccination (Day 84 up to Day 392)
Query!
Secondary outcome [4]
0
0
Group 4: Number of Adult Participants With SAEs Post Booster Vaccination Until EOS
Query!
Assessment method [4]
0
0
Number of adult participants with SAEs post booster vaccination until EOS were reported. AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. SAE were defined as any untoward medical occurrence that at any dose results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.
Query!
Timepoint [4]
0
0
From booster vaccination (Day 84 up to Day 364) until EOS (up to PP Day 366 [Day 366 up to Day 554])
Query!
Secondary outcome [5]
0
0
Group 4: Number of Adult Participants With AESIs Post Booster Vaccination Until EOS
Query!
Assessment method [5]
0
0
Number of adult participants with AESI post booster vaccination until EOS were reported. Thrombosis with thrombocytopenia syndrome (TTS) in adults was considered an AESI in this study. TTS is a syndrome characterized by a combination of both a thrombotic event and thrombocytopenia.
Query!
Timepoint [5]
0
0
From booster vaccination (Day 84 up to Day 364) until EOS (up to PP Day 366 [Day 366 up to Day 554])
Query!
Secondary outcome [6]
0
0
Group 4: Number of Adult Participants With MAAEs Until 6 Months Post Booster Vaccination
Query!
Assessment method [6]
0
0
Number of adult participants with MAAEs until 6 months post booster vaccination were reported. MAAEs were defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically attended visits. New onset of chronic diseases was collected as part of the MAAEs.
Query!
Timepoint [6]
0
0
6 months post booster vaccination (Day 84 up to Day 546)
Query!
Secondary outcome [7]
0
0
Group 4: Number of Adult Participants With AEs Leading to Study Discontinuation Post Booster Vaccination Until EOS
Query!
Assessment method [7]
0
0
Number of adult participants with AEs leading to study discontinuation post booster vaccination until EOS were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. All AEs leading to discontinuation from the study (regardless of the causal relationship) were reported for all adult participants from the moment of booster vaccination until completion of the participant's last study-related procedure.
Query!
Timepoint [7]
0
0
From post booster vaccination (Day 84 up to Day 364) until EOS (up to PP Day 366 [Day 366 up to Day 554])
Query!
Secondary outcome [8]
0
0
Number of Adult Participants With Pregnancy Outcomes
Query!
Assessment method [8]
0
0
Number of adult participants with pregnancy outcomes were reported. Pregnancy outcomes in adult participants included live term birth, live preterm birth, stillbirth, and abortion.
Query!
Timepoint [8]
0
0
From first vaccination on Day 1 until PP Day 1 (Day 7 up to Day 163)
Query!
Secondary outcome [9]
0
0
Number of Adult Participants With Pregnancy Related AEs Throughout Pregnancy
Query!
Assessment method [9]
0
0
Number of adult participants with pregnancy related AEs throughout pregnancy were reported. Pregnancy related AEs in adult participants were collected based on 2 baseline gestational age groups (adult participants who received vaccination at 16 to 27 weeks \[\>=16 weeks to \<28 weeks\] and at 28 to 38 weeks \[\>=28 weeks to \<=38 weeks\]) and included gestational hypertension, foetal growth restriction, haemorrhage in pregnancy, polyhydramnios, pre-eclampsia, premature rupture of membranes, preterm premature rupture of membranes, bradycardia foetal, premature baby, amniorrhexis, foetalgrowth restriction, amniotic fluid volume decreased.
Query!
Timepoint [9]
0
0
From first vaccination on Day 1 until PP Day 1 (Day 7 up to Day 163)
Query!
Secondary outcome [10]
0
0
Serological Response to First Vaccination as Measured by S-ELISA in Adult Participants at All Blood Collection Timepoints Post First Vaccination
Query!
Assessment method [10]
0
0
Serological response to first vaccination as measured by S-ELISA at all blood collection timepoints post first vaccination were reported.
Query!
Timepoint [10]
0
0
Day 1, Day 29, PP Day 1 (Day 7 up to Day 163), PP Day 183 (Day 189 up to Day 345)
Query!
Secondary outcome [11]
0
0
Serological Response to First Vaccination as Measured by Virus Neutralization Assay (VNA) Titers, 28 Days in Adult Participants Post First Vaccination
Query!
Assessment method [11]
0
0
Serological response to first vaccination measured by VNA titers at 28 days in adult participants post first vaccination was reported. Data were expressed as 50 percent (%) inhibitory concentration (IC50) units.
Query!
Timepoint [11]
0
0
28 days post first vaccination on Day 1 (at Day 29)
Query!
Secondary outcome [12]
0
0
Group 4: Serological Response to Booster Vaccination Measured by Binding (S-ELISA) Antibody Titers in Adult Participants at Blood Collection Time Points Post Booster Vaccination
Query!
Assessment method [12]
0
0
Serological response to vaccination as measured by binding (S-ELISA) antibody titers in adult participants at blood collection time points post booster vaccination were reported.
Query!
Timepoint [12]
0
0
Booster Day 1 (Day 84 up to Day 364), Booster Day 29 (Day 112 up to Day 392)
Query!
Secondary outcome [13]
0
0
Group 4: Serological Response to Booster Vaccination Measured by Neutralizing (VNA) Antibody Titers in Adult Participants at Blood Collection Time Points Post Booster Vaccination
Query!
Assessment method [13]
0
0
Serological response to booster vaccination measured by neutralizing VNA antibody titers in adult participants at blood collection time points post booster vaccination were reported. Data were expressed as IC50 units.
Query!
Timepoint [13]
0
0
Booster Day 1 (Day 84 up to Day 364), Booster Day 29 (Day 112 up to Day 392)
Query!
Secondary outcome [14]
0
0
Serological Response to Vaccination as Measured by S-ELISA at Birth (That is, in Cord Blood) and at 2 Months and 6 Months of Age in Neonates and Infants Born to Adult Participants
Query!
Assessment method [14]
0
0
Serological response to vaccination as measured by S-ELISA at birth (that is, in cord blood) and at 2 months and 6 months of age in neonates and infants born to adult participants were reported.
Query!
Timepoint [14]
0
0
At birth (postnatal [PN] Day 1 [Day 7 up to Day 163]), 2 months (up to PN Day 61 [Day 67 up to Day 223]) and 6 months (up to PN Day 183 [Day 189 up to Day 345])
Query!
Secondary outcome [15]
0
0
Serological Response to Vaccination as Measured by VNA Titers at Birth (That is, in Cord Blood) in Neonates and Infants Born to Adult Participants
Query!
Assessment method [15]
0
0
Serological response to vaccination as measured by VNA titers at birth (that is, in cord blood) in neonates and infants born to adult participants were reported. Data were expressed as IC50 units.
Query!
Timepoint [15]
0
0
At Birth (PN Day 1 [Day 7 up to Day 163])
Query!
Secondary outcome [16]
0
0
Number of Neonates and Infants With SAEs (Including MIS-C) From Birth Up to 12 Months of Age in Neonates and Infants Born to Adult Participants
Query!
Assessment method [16]
0
0
An AE is any untoward medical occurrence in participants in the study that does not necessarily have a causal relationship with pharmaceutical/biological agent under study. SAE: any untoward medical occurrence that resulted in following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. MIS-C: a serious and potentially fatal condition in infants and children with SARS-CoV-2, which resulted in inflammation involving multiple organs. Symptoms of MIS-C: persistent fever, fatigue and signs and symptoms including multiorgan systems (cardiac, gastrointestinal, renal, hematologic, dermatologic, neurologic) involvement, elevated inflammatory markers and, in severe cases, hypotension and shock.
Query!
Timepoint [16]
0
0
From birth (PN Day 1 [Day 7 up to Day 163]) up to 12 months of age (up to PN Day 366 [Day 372 up to Day 528])
Query!
Secondary outcome [17]
0
0
Number of Neonates and Infants With AESIs From Birth Until 12 Months of Age in Neonates and Infants Born to Adult Participants
Query!
Assessment method [17]
0
0
Number of neonates and infants with AESIs from birth until 12 months of age in neonates and infants born to adult participants were reported. TTS is a syndrome characterized by a combination of both a thrombotic event and thrombocytopenia.
Query!
Timepoint [17]
0
0
From birth (PN Day 1 [Day 7 up to Day 163]) until 12 months of age (up to PN Day 366 [Day 372 up to Day 528])
Query!
Secondary outcome [18]
0
0
Number of Neonates and Infants With MAAEs From Birth Until 6 Months of Age in Neonates and Infants Born to Adult Participants
Query!
Assessment method [18]
0
0
Number of neonates and infants with MAAEs from birth until 6 months of age in neonates and infants born to adult participants were reported. MAAEs were defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically attended visits. New onset of chronic diseases were collected as part of the MAAEs.
Query!
Timepoint [18]
0
0
From birth (PN Day 1 [Day 7 up to Day 163]) until 6 months of age (up to PN 183 [Day 189 up to Day 345])
Query!
Secondary outcome [19]
0
0
Number of Neonates and Infants With AEs Leading to Study Discontinuation From Birth Until Study Discontinuation
Query!
Assessment method [19]
0
0
Number of neonates and infants with AEs leading to study discontinuation from birth until study discontinuation were reported. An AE is any untoward medical occurrence in participants who does not necessarily have a causal relationship with pharmaceutical/biological agent under study. All AEs leading to discontinuation from the study (regardless of the causal relationship) were reported for all neonates and infants.
Query!
Timepoint [19]
0
0
From birth (PN Day 1 [Day 7 up to Day 163]) until study discontinuation (until 12 months of age [up to PN Day 366 {Day 372 up to Day 528}])
Query!
Secondary outcome [20]
0
0
Number of Neonates and Infants With Different Birth Outcomes From Birth Up to 12 Months of Age
Query!
Assessment method [20]
0
0
Number of neonates and infants with different birth outcomes from birth until 12 months of age were reported. Neonate/infant outcomes included normal neonate, term neonate with (or without) complications, preterm neonate with (or without) complications, neonatal infection, respiratory distress, congenital anomalies, neonatal death, low birth weight, and small for gestational age.
Query!
Timepoint [20]
0
0
From birth (PN Day 1 [Day 7 up to Day 163]) up to 12 months of age (up to PN Day 366 [Day 372 up to Day 528])
Query!
Eligibility
Key inclusion criteria
* If on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination
* Participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at Screening. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled
* Participant will be at second or third trimester of pregnancy, that is, Week 16 to Week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere)
* Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
* Participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
* Participant either received their last COVID-19 vaccination with an authorized/licensed COVID-19 vaccine (at least 4 months prior to first study vaccination) or is COVID 19 vaccine-naïve
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Participants with medical or obstetric histories that put them at higher risk for maternal or fetal complications (example, chronic pregnancy-related disorders, birth defects or genetic conditions during previous pregnancy)
* Participant with abnormal pregnancy screening test (example, ultrasound fetal abnormalities, maternal blood screen)
* Participant has a history of malignancy within 2 years before screening (exceptions are squamous, basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy, considered cured with minimal risk of recurrence)
* Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
* Participant has a history of any serious, chronic, or progressive neurological disorders or seizures including Guillain-Barre syndrome, with the exception of febrile seizures during childhood
* Participant has a positive diagnostic test result (polymerase chain reaction [PCR] based viral ribonucleic acid [RNA] detection) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection at screening or Day 1 (if more than 4 days in between)
* Participant has a history of thrombosis with thrombocytopenia syndrome (TTS), including cerebral venous sinus thrombosis (CVST), or heparin-induced thrombocytopenia (HIT)
* Participant has a history of capillary leak syndrome (CLS)
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/08/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/11/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
51
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Mississippi
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Nebraska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New Mexico
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Belo Horizonte
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Criciúma
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Marilia
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Natal
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Porto Alegre
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Sao Bernardo do Campo
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Sao Jose do Rio Preto
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Sorocaba
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
São Paulo
Query!
Country [14]
0
0
South Africa
Query!
State/province [14]
0
0
Dennilton
Query!
Country [15]
0
0
South Africa
Query!
State/province [15]
0
0
Johannesburg
Query!
Country [16]
0
0
South Africa
Query!
State/province [16]
0
0
Mamelodi East
Query!
Country [17]
0
0
South Africa
Query!
State/province [17]
0
0
Soweto
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Vaccines & Prevention B.V.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04765384
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Janssen Vaccines & Prevention B.V. Clinical Trial
Query!
Address
0
0
Janssen Vaccines & Prevention B.V.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/84/NCT04765384/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/84/NCT04765384/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04765384
Download to PDF